These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 7633940

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M, Wappler F, Weisshorn R, Ulrich Gerbershagen M, Steinfath M, Schulte Am Esch J.
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E, Koob M, Anetseder M, Schoemig P, Krauspe R, Hogrefe G, Engelhardt W.
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [Abstract] [Full Text] [Related]

  • 5. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
    Steinfath M, Seranski P, Singh S, Fiege M, Wappler F, Schulte Am Esch J, Scholz J.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
    [Abstract] [Full Text] [Related]

  • 6. Malignant hyperthermia susceptibility, an autosomal dominant disorder?
    Fagerlund TH, Islander G, Ranklev Twetman E, Berg K.
    Clin Genet; 1997 Jun; 51(6):365-9. PubMed ID: 9237497
    [Abstract] [Full Text] [Related]

  • 7. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL, Pollock AN, Couchman KG, Hodges M, Hutchinson DO, Waaka R, Lynch P, McCarthy TV, Stowell KM.
    Hum Mol Genet; 2000 Jun 12; 9(10):1515-24. PubMed ID: 10888602
    [Abstract] [Full Text] [Related]

  • 8. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
    Rueffert H, Olthoff D, Deutrich C, Meinecke CD, Froster UG.
    Acta Anaesthesiol Scand; 2002 Jul 12; 46(6):692-8. PubMed ID: 12059893
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ryanodine receptor gene point mutation and malignant hyperthermia susceptibility.
    Moroni I, Gonano EF, Comi GP, Tegazzin V, Prelle A, Bordoni A, Bresolin N, Scarlato G.
    J Neurol; 1995 Feb 12; 242(3):127-33. PubMed ID: 7751854
    [Abstract] [Full Text] [Related]

  • 11. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL, Brooks C, Brown SL, Ellis FR, Halsall PJ, Quinnell RJ, Shaw MA, Hopkins PM.
    Hum Mutat; 2002 Aug 12; 20(2):88-97. PubMed ID: 12124989
    [Abstract] [Full Text] [Related]

  • 12. [In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method].
    Rüffert H, Olthoff D, Deutrich C, Thamm B, Froster U.
    Anaesthesist; 2000 Feb 12; 49(2):113-20. PubMed ID: 10756965
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene.
    Deufel T, Sudbrak R, Feist Y, Rübsam B, Du Chesne I, Schäfer KL, Roewer N, Grimm T, Lehmann-Horn F, Hartung EJ.
    Am J Hum Genet; 1995 Jun 12; 56(6):1334-42. PubMed ID: 7762556
    [Abstract] [Full Text] [Related]

  • 16. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles.
    Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Schulte am Esch J.
    Anesth Analg; 1996 Jun 12; 82(6):1230-6. PubMed ID: 8638796
    [Abstract] [Full Text] [Related]

  • 17. Phenotypes associated with malignant hyperthermia susceptibility in swine genotyped as homozygous or heterozygous for the ryanodine receptor mutation.
    Fletcher JE, Calvo PA, Rosenberg H.
    Br J Anaesth; 1993 Sep 12; 71(3):410-7. PubMed ID: 8398525
    [Abstract] [Full Text] [Related]

  • 18. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R, Wappler F, Fiege M, Gerbershagen MU, Kolodzie K, Alberts P, Horn EP, Schulte Am Esch J.
    J Clin Anesth; 2004 Aug 12; 16(5):353-7. PubMed ID: 15374556
    [Abstract] [Full Text] [Related]

  • 19. The ryanodine contracture test may help diagnose susceptibility to malignant hyperthermia.
    Reuter DA, Anetseder M, Müller R, Roewer N, Hartung EJ.
    Can J Anaesth; 2003 Aug 12; 50(7):643-8. PubMed ID: 12944436
    [Abstract] [Full Text] [Related]

  • 20. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
    Roberts MC, Mickelson JR, Patterson EE, Nelson TE, Armstrong PJ, Brunson DB, Hogan K.
    Anesthesiology; 2001 Sep 12; 95(3):716-25. PubMed ID: 11575546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.